Pregnancy Relevant Products

Information

The term TORCH encompasses all infectious agents that can be transferred from mother to child in the uterus, during birth or after birth via vertical infection. It includes Toxoplasma gondii, rubella virus, cytomegalovirus (CMV), herpes simplex virus (HSV) and other pathogens such as Chlamydia trachomatis, parvovirus B19, Treponema pallidum and varicella zoster virus (VZV).

Diagnostic Guidelines

Analysis of antibodies against TORCH parameters is an essential part of pre-, peri- and postnatal care. The tests allow the immune status of the mother to be established and the risks to an existing pregnancy assessed. TORCH tests are generally performed during the first trimester of pregnancy, but they can also be carried out on the newborn if an infection is suspected. The initial investigation of antibodies against TORCH pathogens is aimed at determining the immune status of the mother in order to be able to differentiate between acute primary and past infections or reactivations during the course of pregnancy. If diagnosed early, TORCH infections can in part be effectively treated, reducing the risk of birth defects or loss of the fetus.

Primary infections during pregnancy are especially feared since they are associated with an increased risk of damage to the child.

Pregnancy-relevant products

For Research Use Only. Not For Use In Diagnostic Procedures.
The individual product regulatory statements may vary, please refer to the instructions for use for more information.

Method:

Parameter:

Substrate:

Species/ Antigen:

wdt_ID	Method	Parameter	Substrate	Species/ Antigen
166	IFA	antibodies against Treponema pallidum unspecific FTA IgG positive control
167	IFA	antibodies against Treponema pallidum unspecific FTA IgM positive control
168	IFA	Treponema pallidum (FTA-ABS)	bacterial smear verification BIOCHIP (2 BIOCHIPs per field)	T. pallidum
169	IFA	Treponema pallidum FTA negative control
170	ELISA	Treponema pallidum	antigen-coated microplate wells	recombinant antigens 15 kDa, 17 kDa, 47 kDa, 42 kDa (TmpA)
171	ELISA	Treponema pallidum incl. IgG/RF absorbent	antigen-coated microplate wells	microplate wells recombinant antigens 15 kDa, 17 kDa, 47 kDa, 42 kDa (TmpA)
172	ELISA	Treponema pallidum Screen ELISA	antigen-coated microplate wells	recombinant antigens 15 kDa, 17 kDa, 47 kDa, 42 kDa (TmpA)
173	EUROLINE	positive control serum: IgG, human, 50x concentrated for Treponema pallidum
174	EUROLINE	positive control serum: IgM, human, 50x concentrated for Treponema pallidum
175	EUROLINE	Treponema pallidum (TpN15, TpN17, TmpA, TpN47 separately)	EUROLINE
176	WESTERNBLOT	antibodies against Treponema pallidum IgG positive control
177	WESTERNBLOT	antibodies against Treponema pallidum IgM positive control
178	WESTERNBLOT	Treponema pallidum	Westernblot	15 kDa, 17 kDa, 45 kDa (tmpA), 47 kDa
179	IFA	antibodies against Treponema pallidum IgG positive control for FTA absorption
180	WESTERNBLOT	EUROLINE-WB Treponema pallidum plus cardiolipin	Westernblot	15 kDa, 17 kDa, 45 kDa (tmpA), 47 kDa plus purified cardiolipin
181	ELISA	CSQ pair of controls anti-Treponema pallidum (IgG)
182	ELISA	Treponema pallidum antibody determination in CSF	antigen-coated microplate wells	recombinant antigens 15 kDa, 17 kDa, 47 kDa, 42 kDa (TmpA)
183	IFA	Treponema pallidum (FTA-ABS)	bacterial smears verification BIOCHIP (3 BIOCHIPs per field)	T. pallidum T. phagedenis
184	IFA	antibodies against Chlamydia trachomatis IgA positive control
185	IFA	antibodies against Chlamydia trachomatis IgG positive control
186	IFA	antibodies against Chlamydia trachomatis IgM positive control
187	IFA	Chlamydia trachomatis	infected cells	EU 40
188	ELISA	Chlamydia trachomatis	antigen-coated microplate wells	native MOMP antigen from C. trachomatis
189	ELISA	Chlamydia trachomatis	antigen-coated microplate wells	native MOMP antigen from C. trachomatis
190	ELISA	Chlamydia trachomatis incl. IgG/RF absorbent	antigen-coated microplate wells	native MOMP antigen from C. trachomatis
	Method	Parameter	Substrate	Species/ Antigen